1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Mersana Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b upifitamab rilsodotin - Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Mersana Therapeutics | 523 | 2017-12-12 | 2023-11-13 |
United States (1)